| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KMT2E |
| Uniprot No | Q8IZD2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 151-450aa |
| 氨基酸序列 | RQHIPDTYLCERCQPRNLDKERAVLLQRRKRENMSDGDTSATESGDEVPVELYTAFQHTPTSITLTASRVSKVNDKRRKKSGEKEQHISKCKKAFREGSRKSSRVKGSAPEIDPSSDGSNFGWETKIKAWMDRYEEANNNQYSEGVQREAQRIALRLGNGNDKKEMNKSDLNTNNLLFKPPVESHIQKNKKILKSAKDLPPDALIIEYRGKFMLREQFEANGYFFKRPYPFVLFYSKFHGLEMCVDARTFGNEARFIRRSCTPNAEVRHEIQDGTIHLYIYSIHSIPKGTEITIAFDFDY |
| 预测分子量 | 42.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KMT2E重组蛋白的3篇参考文献的简要概括(基于已有研究领域推测，具体文献需进一步验证)：
---
1. **文献名称**: *MLL5 (KMT2E): Structure, Function, and Clinical Relevance*
**作者**: Ali, M., et al.
**摘要**: 该研究利用重组KMT2E蛋白，解析其甲基转移酶结构域的三维结构，并验证其组蛋白H3K4甲基化活性，探讨其在造血干细胞分化中的调控作用。
2. **文献名称**: *Enzymatic characterization of recombinant KMT2E reveals substrate specificity and regulatory mechanisms*
**作者**: Cao, L., et al.
**摘要**: 通过重组表达KMT2E蛋白，系统分析其酶动力学参数及底物选择性，发现其活性依赖特定辅因子，并揭示其在表观遗传修饰中的独特功能。
3. **文献名称**: *KMT2E interacts with the NuRD complex to regulate gene expression via chromatin remodeling*
**作者**: Smith, J., et al.
**摘要**: 研究通过重组KMT2E蛋白与NuRD复合体的体外结合实验，证明二者协同调控染色质结构，影响靶基因转录，为白血病发生机制提供新见解。
---
**注意**：上述文献为示例性概括，实际引用时需核实具体文献是否存在及内容准确性。建议通过PubMed或Google Scholar以关键词“KMT2E recombinant”“MLL5 recombinant protein”等检索最新研究。
**Background of KMT2E Recombinant Protein**
KMT2E (lysine methyltransferase 2E), also known as MLL5. is a member of the KMT2 family of histone methyltransferases, which play critical roles in regulating gene expression through epigenetic modifications. Unlike other KMT2 members, KMT2E lacks a canonical catalytic SET domain but retains methyltransferase activity through a divergent SET-like domain, enabling mono- and di-methylation of histone H3 lysine 4 (H3K4). This enzyme is involved in diverse cellular processes, including cell cycle regulation, DNA damage repair, and stem cell differentiation.
Recombinant KMT2E protein is engineered for in vitro studies to dissect its molecular mechanisms and interactions. Typically produced in bacterial or mammalian expression systems, the recombinant protein retains functional domains, such as the catalytic region and PHD fingers, which mediate chromatin binding. Its production often involves affinity tags (e.g., GST or His-tag) for purification and detection.
Research highlights KMT2E’s dual role in cancer: it acts as a tumor suppressor in myeloid malignancies but may promote oncogenesis in solid tumors. Dysregulation of KMT2E is linked to hematopoiesis defects, leukemia, and metabolic disorders. Recombinant KMT2E enables biochemical assays (e.g., methyltransferase activity profiling), structural studies, and inhibitor screening. Additionally, it aids in exploring its partnership with proteins like MOF/NSL complex members or retinoblastoma proteins in chromatin remodeling.
The development of KMT2E recombinant tools has advanced understanding of its non-canonical methylation mechanisms and its crosstalk with other epigenetic regulators, offering potential therapeutic avenues for diseases driven by KMT2E dysfunction.
×
